Real-world effectiveness and tolerability of cannabidiol in pediatric and adult patients with developmental and epileptic encephalopathies: a retrospective single-center study
Background Developmental and epileptic encephalopathies (DEEs) are severe, drug-resistant epilepsies commonly associated with behavioral and cognitive impairment. Cannabidiol (CBD) is approved as adjunctive therapy for seizures associated with Dravet syndrome, Lennox–Gastaut syndrome, and tuberous sclerosis complex, but real-world evidence on outcomes beyond seizure control, and in patients treated outside these approved indications, remains limited. We performed a retrospective single-center study of pediatric and adult patients with DEEs who started adjunctive CBD between 2015 and 2025, to evaluate its real-world effectiveness and tolerability on seizure, behavioral, and cognitive outcomes at 3, 6, and 12 months. Results Fifty patients were included (mean age 22.1 ± 11.6 years; 58% female); 62% had combined focal and generalized seizures, and among generalized seizures, tonic–clonic seizures were the most frequent type (32%). A genetic etiology was identified in 48% of patients. Median monthly seizure frequency decreased from 31 at baseline to 16 at 6 months (p = 0.005) and 8 at 12 months (p = 0.007), and a ≥ 50% reduction in seizure frequency was achieved in 30.8%, 64.0%, and 48.0% of patients at 3, 6, and 12 months, respectively. Caregiver-reported behavioral improvement was noted in 34.8% and 33.3% of patients at 6 and 12 months, and cognitive improvement in 36.4% and 25.0%, respectively. At 6 months, cognitive improvement was associated with the absence of psychomotor delay (p = 0.011), a diagnosis of Dravet syndrome (p = 0.036), and lower intellectual disability severity (p = 0.005). Adverse events occurred in 50% of patients, most commonly somnolence; no serious adverse events were reported. Conclusions Adjunctive CBD was associated with a clinically meaningful reduction in seizure frequency, particularly for convulsive seizures. Improvements in behavioral and cognitive domains were observed in up to one-third of patients, supporting a broader clinical benefit beyond seizure control in this population.
Authors
- Laura Abraira (ORCID: https://orcid.org/0000-0002-5119-7929)
- Júlia Sala‐Coromina (ORCID: https://orcid.org/0000-0001-5116-6316)
- Samuel López‐Maza (ORCID: https://orcid.org/0000-0003-3660-2604)
- Miquel Raspall‐Chaure (ORCID: https://orcid.org/0000-0002-3132-3342)
- Daniel Campos (ORCID: https://orcid.org/0000-0003-4795-5309)
- Paula Arranz
- Teresa Jordà-Baleri (ORCID: https://orcid.org/0009-0005-5255-5475)
- Isabel Pava-Bernat
- Manuel Toledo
- Elena Fonseca
- Maria Garcés
- Manuel Quintana
- Estevo Santamarina
Institutions
- Vall d'Hebron Institut de Recerca (ES)
- Vall d'Hebron Hospital Universitari (ES)
Publication Details
- Journal
- Research Square
- Published
- 2026-11-19
- DOI
- https://doi.org/10.21203/rs.3.rs-10852406/v1
- Primary Topic
- Epilepsy research and treatment
- Type
- preprint